ALNY vs LLY · P/E 76, rev $1.29B vs P/E 39, rev $22.97B
Alnylam Pharmaceuticals Inc (ALNY) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the ALNY and LLY stock pages for the full models.
Not investment advice.